Relmada Therapeutics
RLMD | NASDAQ
$3.61
-$0.60 (-14.25%)
At close: Nov 16, 2026, 4:00 PM ET
$3.61
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Relmada Therapeutics Company Profile
Company profile explainedCompany Profile
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Key Executives
| Name | Position |
|---|---|
| Sergio Traversa | Chief Executive Officer & Director |
| Maged S. Shenouda | Chief Financial Officer |
| Paul E. Kelly | Chief Operating Officer & Director |
| Andrew Cutler | Senior Clinical Development Advisor |
| Bipin K. Dalmia | Chief Business Officer |
| Charles S. Ence | Chief Accounting & Compliance Officer |
| Gina DiGuglielmo | Vice President & Head of Clinical Operations |
| Raj S. Pruthi | Chief Medical Officer of Urology |
| Richard Mangano | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 11, 2026 | 4 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 28, 2026 | 8-K | Current Report |
| Jun 22, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jun 18, 2026 | S-8 | Filing |
Relmada Therapeutics
| Country | United States |
| IPO Date | Jun 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Sergio Traversa |
Contact Details
2222 Ponce de Leon Blvd. Coral Gables,
Florida 33134 United States
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove RLMD